Black Diamond Therapeutics (BDTX) financial statements
Black Diamond Therapeutics reported revenue of $70M in fiscal 2025.
Net income was $22M.
The diluted share count rose 2752% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Black Diamond Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — | $0 | $70M |
| Research and development | $7M | $22M | $48M | $97M | $64M | $59M | $51M | $34M |
| Selling, general and admin | $2M | $8M | $21M | $30M | $28M | $27M | $27M | $17M |
| Operating income | -$9M | -$29M | -$70M | -$127M | -$93M | -$86M | -$79M | $13M |
| Interest expense | — | $0 | $1,000 | $0 | — | — | — | — |
| Pre-tax income | — | — | -$67M | -$125M | -$91M | -$83M | -$70M | $22M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9M | -$35M | -$67M | -$126M | -$91M | -$82M | -$70M | $22M |
| EPS (diluted) | -$4.42 | -$16.99 | -$2.05 | -$3.47 | -$2.52 | -$1.88 | -$1.27 | $0.39 |
| Diluted shares | 2M | 2M | 33M | 36M | 36M | 44M | 55M | 58M |
| Operating margin | — | — | — | — | — | — | — | 17.9% |
| Net margin | — | — | — | — | — | — | — | 32.0% |
Balance sheet
Fiscal years, from Black Diamond Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $52M | $155M | $315M | $210M | $123M | $131M | $99M | $129M |
| Total current assets | $52M | $156M | $320M | $216M | $128M | $134M | $101M | $132M |
| Property, plant and equipment | $134,000 | $164,000 | $385,000 | $3M | $3M | $2M | $1M | $365,000 |
| Total assets | $52M | $158M | $330M | $248M | $156M | $159M | $123M | $143M |
| Total current liabilities | $3M | $5M | $14M | $24M | $15M | $20M | $21M | $16M |
| Total liabilities | $7M | $5M | $22M | $52M | $41M | $42M | $39M | $31M |
| Shareholders' equity | -$16M | -$47M | $308M | $196M | $116M | $117M | $83M | $112M |
| Net debt | -$52M | -$155M | -$35M | -$66M | -$34M | -$56M | -$36M | -$21M |
Cash flow
Fiscal years, from Black Diamond Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8M | -$25M | -$52M | -$100M | -$85M | -$67M | -$62M | $30M |
| Capital spending | $76,000 | $21,000 | $142,000 | $3M | $192,000 | $33,000 | $0 | — |
| Free cash flow | -$9M | -$25M | -$52M | -$103M | -$85M | -$67M | -$62M | — |
| Stock-based compensation | $64,000 | $4M | $8M | $14M | $12M | $10M | $11M | $7M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BDTX.
Open BDTX in InvestinglyQuestions
What was Black Diamond Therapeutics's revenue in 2025?
$70M in fiscal 2025, from its 10-K filing.
From Black Diamond Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.